Smoking, leading to over 438,000 annual deaths in the US and 92 billion US dollars in lost productivity, is an important risk factor for several diseases. Global smoking statistics for 2002 have shown that 80,000 to 100,000 children worldwide start smoking every day. Human biomonitoring nowadays has provided an efficient and cost-effective means of measuring human exposures and biological effects of smoking. To review the utility of biomarkers in reflecting the hazard from cigarette smoking, we comprehensively searched the Cochrane Library, Medline and EMbase from 1966 to May 2010 with the language limit of English. We found that the currently used biomarkers, such as tobacco-specific metabolites, smoking-induced genotoxic products, may not scientifically reflect the hazard from cigarette smoking. More research is needed to find out more effective biomarkers for estimating hazards from cigarette smoking. This paper is expected to help researchers understand the current utilization of biomarkers related to cigarette smoking and to provide suggestive guides to tobacco companies in producing less-toxic cigarettes, thus to provide a safe way to smoke.
Get full access to this article
View all access options for this article.
References
1.
Andelid K., Bake B., Rak S., Lindén A., Rosengren A., and Ekberg-Jansson A. (2007) Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms . Respiratory Medicine101: 888-895.
2.
Angerer J., Ewers U., and Wilhelm M. ( 2007) Human biomonitoring: State of the art. Environmental Health210: 201-228.
3.
Barnes PJ, Shapiro SD, and Pauwels RA ( 2003) Chronic obstructive pulmonary disease: molecular and cellular mechanisms. European Respiratory Journal22: 672-688.
4.
Bartecchi CE, MacKenzie TD, and Schrier RW ( 1994) The human costs of tobacco use (1). New England Journal of Medicine330: 907-912.
5.
Benowitz NL ( 1996) Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiology Review18(2): 188-204.
6.
Benowitz NL, Jacob P. III, Ahijevych K., Jarvis MJ, Hall S., LeHouezec J., et al. (2002) Biochemical verification of tobacco use and cessation. Nicotine Tobacco Research4(2): 149-159.
7.
Benowitz NL, Perez-Stable J., Fong I., Modin G., Herrera B., and Jacob P. 3rd (1999) Ehnic differences in N-glucuronidaton of nicotine and cotinine. Journal of Pharmacology Experiment Therapy291: 1196-1203.
8.
Benowitz NL, Schulta KE, Haller CA, Wu AH, Dains KM, Jacob P.3rd, et al. (2009) Prevalence of smoking assessed biochemically in an Urban public hospital: a rationale for routine cotinine screening. American Journal of Epidemiology170: 885-891.
9.
Bernert JT, Gordon SM, Jain RB, Brinkman MC, Sosnoff CS, Seyler TH, et al. (2009) Increases in tobacco exposure biomarkers measured in non-smokers exposed to sidestream cigarette smoke under controlled conditions . Biomarkers14(2): 82-93.
10.
Caraballo RS, Giovino GA, Pechachek TF, Mowery PD, Richter PA, Strauss WJ, et al. (1998) Racial and ethnic differences in serum cotinine levels of cigarette smokers. Third National Health and Nutrition Examination Survey. The Journal of the American Medical Association280: 135-139.
11.
Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, and Wu JT ( 2003) Elevated cell-free serum DNA detected in patients with myocardial infarction. Clinica Chimica Acta327: 95-101.
12.
Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research18(10): 997-1006.
13.
Colquhoun DR, Goldman LR, Cole RN, Gucek M., Mansharamani M., Witter FR, et al. (2009) Global screening of human cord blood proteomes for biomarkers of toxic exposure and effect. Environment Health Perspective117: 832-838.
14.
Dallongeville J., Marecaux N., Fruchart J-C., and Amouye P. ( 1998) Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta-analysis. Journal of Nutrition128: 1450-1457.
15.
Esquela-Kerscher A. and Slack FJ ( 2006) Oncomirs: MicroRNAs with a role in cancer. Nature Review Cancer6: 259-269.
16.
Hathcock JN, Azzi A., Blumberg J., Bray T., Dickinson A., Frei B., et al. (2005) Vitamins E and C are safe across a broad range of intakes. American Journal Clinical Nutrition81: 736-745.
17.
Hoffmann D. and Hecht S. ( 1990) Chemical Carcinogenesis and Mutagenesis, London: Springer Verlag, 63-102.
18.
Huang YC, Yang SJ, Zhang J., Tan LL, Jiang FL, Li N., et al. (2010) MicroRNAs as promising biomarkers for diagnosing human cancer. Cancer Investigation28: 670-671.
19.
Izzotti A., Calin GA, Steele VE, Croce CM, and Flora Silvio De (2009) Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and ling . The FASEB Journal23: 3243-3250.
20.
Kobayashi H., Kanoh S., and Motoyoshi K. ( 2008) Serum surfactant protein-A, but not surfactant protein-D or KL-6, can predict preclinical lung damage induced by smoking. Biomarkers13(4): 385-392.
21.
Lu J., Getz G., Miska EA, Alvarez-Saavedra E., Lamb J., Peck D., et al. (2005) MicroRNA expression profiles classify human cancers. Nature435: 834-838.
22.
Madsen C., Nafstad P., Eikvar L., Schwarze PE, Rønningen KS, and Haaheim LL ( 2007) Association between tobacco smoke exposure and levels of C-reactive protein in the Oslo II Study. European Journal of Epidemiology22: 311-317.
23.
Negri E., La Vecchia C., D’Avanzo B., and La Malfal RG ( 1994) Acute myocardial infarction: association with time since stopping smoking in Italy; GISSI-EFRIM investigators-Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto-Epidemiologia dei Fattori di Rischio dell’Infarto Miocardico. Journal of Epidemiology Community Health48: 129-133.
24.
O’Neill CA, Halliwell B., van der Vliet A., Davis PA, Packer L., Tritschler H., et al. (1994) Aldehyde-induced protein modifications in human plasma: protection by glutathione and dihydrolipoic acid. Journal of Laboratory Clinical Medicine124: 359-370.
25.
Pignatelli B., Li CQ, Boffetta P., Chen Q., Ahrens W., Nyberg F., et al. (2001) Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Research61: 778-784.
26.
Pinto-Plata VM, Mullerova H., Toso JF, Feudjo-Tepie M., Soriano JB, Vessey RS, et al. (2006) C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax61: 23-28.
27.
Pryor WA, Prier DG, and Church DF ( 1983) Electron-spin resonance study of mainstream and sidestream cigarette smoke: nature of the free radicals in gas-phase smoke and in cigarette tar. Environmental Health Perspectives47: 345-355.
28.
Rainer TH, Wong LK, Lam W., et al. (2003) Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clinica Chemica49: 562-569.
29.
Shah PK and Helfant RH ( 1988). Smoking and coronary artery disease. Chest94: 449-452.
30.
Wannamethee SG, Lowe GD, Shaper AG, Rumley A., Lennon L., Whincup PH ( 2005) Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. European Heart Journal26: 1765-1773.
31.
Williams AE ( 2008) Functional aspects of animal microRNAs. Cellular and Molecular Life Sciences65: 545-562.
32.
Yeh CC, Graham Barr R., Powell CA, Mesia-Vela S., Wang Y., Hamade NK, et al. (2008) No effect of cigarette smoking dose on oxidized plasma proteins. Environmental Research106(2): 219-225.
33.
Yin Z., Zhou B., He Q., Li M., Guan P., Li X., et al. (2009) Association between polymorphisms in DNA repair genes and survival of nonsmoking female patients with lung adenocarcinoma . BMC Cancer9: 439.
